Central composite design for the formulation and optimization of a multi-unit potential colonic drug delivery system of budesonide for ulcerative colitis

Pharmazie

Volumn 66, Issue 2, 2011, Pages 124-129

  Patel, Nirav V ^a   Patel, Jayvadan K ^b   Shah, Shreeraj H ^c   Patel, Jagruti N ^d  

^a ANAND PHARMACY COLLEGE   (India)

^b NOOTAN PHARMACY COLLEGE   (India)

^c LJ Institute of Pharmacy and Research Center Ahmedabad   (India)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE; EUDRAGIT; EUDRAGIT RS; ANTIINFLAMMATORY AGENT; METHYLMETHACRYLATE METHACRYLIC ACID COPOLYMER; METHYLMETHACRYLATE-METHACRYLIC ACID COPOLYMER; POLYMETHACRYLIC ACID DERIVATIVE;

ARTICLE; COLON; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG FORMULATION; DRUG PELLET; DRUG RELEASE; FLUIDIZED BED; HYDROPHILICITY; INDEPENDENT VARIABLE; POWDER; PROCESS OPTIMIZATION; ULCERATIVE COLITIS; ALGORITHM; CHEMISTRY; COMPUTER PROGRAM; HUMAN; ISCHEMIC COLITIS; METABOLISM; SCANNING ELECTRON MICROSCOPY; SOLUBILITY; SURFACE PROPERTY; THEORETICAL MODEL;

ALGORITHMS; ANTI-INFLAMMATORY AGENTS; BUDESONIDE; CHEMISTRY, PHARMACEUTICAL; COLITIS, ISCHEMIC; COLON; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; MICROSCOPY, ELECTRON, SCANNING; MODELS, THEORETICAL; POLYMETHACRYLIC ACIDS; SOFTWARE; SOLUBILITY; SURFACE PROPERTIES;

EID: 79955085643     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2011.0260     Document Type: Article

References (16)

1. Ashford M, Fell JT (1994) Targeting drugs to the colon: delivery systems for oral administration. J Drug Targeting 2: 241-258.
2. Abu Izza K, Garcia Contreras L, Lu DR (1996) Preparation and evaluation of zidovidune-loaded sustained-release microspheres. Optimization of multiple response variables. J Pharm Sci 85: 572-576.
3. Amighi K, Timmermans J, Puigdevall J, Baltes E, Moes AJ (1998) Peroral sustained-release film-coated pellets as a means to overcome physicochemical and biological drug related problems. I. In vitro development and evaluation. Drug Dev Ind Pharm 24: 509-515. (Pubitemid 28273117)
4. Bodea A, Leucuta SE (1997) Optimization of propranolol hydrochloride sustained release pellets using a factorial design. Int J Pharm 154: 49-57. (Pubitemid 27326819)
5. Chourasia MK, Jain SK (2003) Pharmaceutical approaches to colon targeted drug delivery systems. J Pharm Pharm Sci 6: 33-66. (Pubitemid 37207241)
6. Edsbäcker S, Bengtsson, B, Larsson P, Lundinn P, Nilsson A, Ulmius J, Wollmer A (2003) A pharmacoscintigraphic evaluation of oral budesonide given as controlled-release (Entocort) capsules. Aliment Pharmacol Ther 17: 525-536. (Pubitemid 36388753)
7. Friend D (2005) New oral delivery systems for treatment of inflammatory bowel disease. Adv Drug Del Rev 57: 247-265.
8. Fedorak RN, Bistritz L (2005) Targeted delivery, safety, and efficacy of oral enteric-coated formulations of budesonide. Adv Drug Deliv Rev 57: 303-16. (Pubitemid 39536104)
9. Hileman GA, Goskonda SR, Spalitto AJ, Upadrashta SM (1993) Response surface optimization of high dose pellets by extrusion and spheronization. Int J Pharm 100: 71-79. (Pubitemid 23316318)
10. Li SP, Feld KM, Kowarski CR (1997) The effect of polymer coating systems on the preparation, tableting, and dissolution properties of sustained-release drug pellets. Drug Dev Ind. Pharm 23: 623-631. (Pubitemid 27261739)
11. Mrsny RJ (1992) Drug absorption in the colon: a critical review. In: Friend, DR (ed). Oral Colon-Specific Drug Delivery CRC Press, Boca Raton, pp. 1-44.
12. Rubinstein A (1995) Approaches and opportunities in colon specific drug delivery. Crit Rev Ther Drug Carrier Syst 12: 101-149.
13. Röhm GmbH and Rohm America (1999) Eudragit literature.
14. Van den Mooter G, Kinget R. (1995) Oral colon-specific drug delivery: a review. Drug Delivery 2: 81-93.
15. Watts PJ, Illum L (1997) Colonic drug delivery. Drug Dev Ind Pharm 23: 893-913. (Pubitemid 27406363)
16. Zhou F, Vervaet C, Massart DL, Massart B, Remon JP (1998) Optimization of the processing of matrix pellets based on the combination of waxes and starch using experimental design. Drug Dev Ind. Pharm 24: 353-358. (Pubitemid 28204504)